News Releases

Date	Title and Summary	View
Feb 11, 2020	Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine Janssen joins forces with Biomedical Advanced Research and Development Authority (BARDA) to protect communities against threat of a global COVID-19 pandemic NEW BRUNSWICK, N.J. , Feb. 11, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Janssen Pharmaceutical Companies
Feb 10, 2020	Janssen Announces Submission to U.S. FDA for New DARZALEX® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
Jan 30, 2020	Janssen Announces European Commission Approval for Expanded Use of Erleada®▼ (apalutamide) for Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer
Jan 29, 2020	Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat Initiating Vaccine Development and Providing Supplies of Antiviral Medicines to China for Investigational Use NEW BRUNSWICK, N.J. , Jan. 29, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a
Jan 23, 2020	The European Commission Approves Expanded Use Of JANSSEN’S STELARA® (USTEKINUMAB) For The Treatment Of Paediatric Patients With Moderate To Severe Plaque Psoriasis
Jan 22, 2020	Johnson & Johnson Reports 2019 Fourth-Quarter And Full Year Results: - 2019 Fourth-Quarter Sales of $20.7 Billion reflecting growth of 1.7%, operational growth of 2.6%* and adjusted operational growth of 3.4%* - 2019 Full-Year Sales of $82.1 Billion reflecting growth of 0.6%, operational growth of 2.8%* and adjusted operational growth of 4.5%* - 2019 Fourth-Quarter
Jan 20, 2020	European Commission Approves Darzalex®▼ (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
Jan 20, 2020	Janssen Seeks Expanded Use of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
Jan 15, 2020	Janssen Seeks Expanded Use of SPRAVATO®▼ (Esketamine) Nasal Spray in Europe as a Treatment for Depressive Symptoms in Adults with Major Depressive Disorder Who Have Current Suicidal Ideation with Intent
Jan 02, 2020	Johnson & Johnson Announces Quarterly Dividend for First Quarter 2020 NEW BRUNSWICK, N.J., Jan. 2, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2020 of $0.95 per share on the company's common stock. The dividend is payable on March 10, 2020 to shareholders of